ATLANTA, Oct. 18 /PRNewswire-FirstCall/ -- CryoLife, Inc. , a biomaterials, medical device and tissue processing company, announced today that it will conduct its annual Cardiac Surgery Fellows Allograft Symposium on October 19, 2007, at the Company’s corporate headquarters training facility in Kennesaw, Ga. The program will include discussions and demonstrations of surgical techniques of aortic valve replacement and thoracoabdominal aortic aneurysm repair, as well as provide a practical laboratory in which to demonstrate and practice the techniques for proper implant site preparation and allograft implantation.
The keynote speaker will be David C. McGiffin, M.D., Associate Director, Division of Cardiothoracic Surgery and Chief, Section of Cardiopulmonary Transplantation at the University of Alabama, Birmingham, Ala. The program will be attended by 27 surgery fellows from major U.S. surgical training institutions, and will be directed by Paul E. Stelzer, M.D., Senior Faculty, Cardiothoracic Surgery, Mount Sinai School of Medicine, New York, N.Y.
Three additional distinguished cardiovascular surgeons complete the faculty of this program: John W. Fehrenbacher, M.D., Department of Cardiothoracic Surgery, CORVASC, Indianapolis, Ind; Francis Robicsek, M.D., Ph.D., Chairman, Department of Thoracic and Cardiovascular Surgery, Carolinas Medical Center, Charlotte, N.C.; and Craig R. Saunders, M.D., Chairman, Cardiothoracic Surgery, Saint Barnabas Health Care System, Newark, N.J.
“The Cardiac Surgery Fellows Allograft Symposium creates a unique atmosphere in which to engage in thought provoking discussions about complex surgical procedures with leading cardiovascular surgeons in the field,” said Dr. Stelzer. “The additional opportunity to practice allograft implantation techniques in a wet lab environment offers an invaluable educational opportunity for these cardiac fellows.”
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company’s BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O’Brien(R) stentless porcine heart valve and the SG Model 100 vascular graft, which are CE marked for distribution within the European Community.
For additional information about the company, visit CryoLife’s Web site: http://www.cryolife.com
CONTACT: D. Ashley Lee, Executive Vice President, Chief Operating Officer
and Chief Financial Officer, CryoLife, Inc., +1-770-419-3355; or Katie
Brazel, Fleishman-Hillard, +1-404-739-0150
Web site: http://www.cryolife.com//
